WAVRE, Belgium — 24 April 2025: iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announces positive five-year data from the STAR-GLOBAL trial for the ...
WAVRE, Belgium, July 10, 2019 /PRNewswire/ -- iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, today announced consistent 18-month ...
- The trial demonstrated that the implantation of MINIject resulted in an average 32.6% IOP reduction to a mean of 15.6mmHg at one year. In addition, 75% of patients were able to discontinue topical ...
WAVRE, Belgium — 10 January 2024: iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announces that the first implantations of MINIject ®, the Company’s ...
Please provide your email address to receive an email when new articles are posted on . Nearly 90% of participants achieved a reduction in IOP of 20% or greater. Endothelial cell density loss was less ...
-- Five-year safety profile including corneal health confirmed and 38% IOP reduction sustained -- Over 5000 patients benefiting from limited commercial rollout of MINIject(R) worldwide to-date -- ...
WAVRE, Belgium, Dec. 19, 2018 /PRNewswire/ -- iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, today announced exceptional ...
Five-year safety profile including corneal health confirmed and 38% IOP reduction sustained Over 5000 patients benefiting from limited commercial rollout of MINIject ® worldwide to-date iSTAR Medical ...
STAR-GLOBAL is an extension trial of the initial EU clinical trials investigating the long-term safety and efficacy of MINIject ® in patients with up to five-years of follow-up. Patients implanted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results